Literature DB >> 34034750

Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis.

Yani Ke1, Shan Liu2, Zheyuan Zhang3, Jie Hu4.   

Abstract

BACKGROUND: Angiopoietin-like proteins (ANGPTLs) are closely related to insulin resistance and lipid metabolism, and may be a key in metabolic syndrome. Non-alcoholic fatty liver disease (NAFLD) (newly named metabolic-associated fatty liver disease (MAFLD)) is based on metabolic dysfunction. There may be some correlation between ANGPTLs and MAFLD, but the specific correlation is unclear. This study aims to explore the predictive role of ANGPTLs in MAFLD and its progression.
METHODS: Seven databases (PubMed, EMBASE, Cochrane Library, CNKI, WANFANG, CBM and Clinicaltrials.gov ) were searched with free terms and MeSH terms. The random-effects model was used to pool the data, and Standardized Mean Difference (SMD) and 95% confidence intervals (CI) were taken as the overall outcome. No language restrictions existed in the article selection. RevMan 5.3, Stata 16 and MetaXL software were applied to analyse the data and the GRADE system was utilized to assess the certainty of evidence.
RESULTS: After reviewing 823 related articles, 13 studies (854 cases and 610 controls) met the inclusion criteria, and contributed to this meta-analysis. The results showed that circulating ANGPTL8 level was significantly elevated in the MAFLD group than in the healthy control group (SMD = 0.97 pg/mL, 95%CI: 0.77, 1.18). Conversely, there was no significant difference in the ANGPTL4 (SMD = 0.11 ng/mL, 95%CI: - 0.32, 0.54) and ANGPTL3 (SMD = - 0.95 ng/mL, 95%CI: - 4.38, 2.48) between the two groups. Subgroup analysis showed that: 1) the MAFLD group had significantly higher ANGPTL8 levels than the healthy control group in Asian and other races; 2) the ANGPTL8 levels in Body Mass Index (BMI) > 25 kg/m2 patients with MAFLD were higher than those in the healthy control group; 3) the higher ANGPTL8 levels were observed in moderate to severe MAFLD group than the healthy control group. Meta-regression demonstrated that BMI might effectively explain the high heterogeneity. No significant publication bias existed (P > 0.05). The certainty of evidence was assessed as very low by the GRADE system.
CONCLUSIONS: The ANGPTLs may be related to MAFLD. The increased ANGPTL8 level may be positively correlated with different situations of MAFLD, which may act as a potential indicator to monitor the development trends.

Entities:  

Keywords:  Angiopoietin-like protein 8; Angiopoietin-like proteins; Meta-analysis; Metabolic-associated fatty liver disease; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Mesh:

Substances:

Year:  2021        PMID: 34034750      PMCID: PMC8152125          DOI: 10.1186/s12944-021-01481-1

Source DB:  PubMed          Journal:  Lipids Health Dis        ISSN: 1476-511X            Impact factor:   3.876


  38 in total

1.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.

Authors:  Andreas Stang
Journal:  Eur J Epidemiol       Date:  2010-07-22       Impact factor: 8.082

Review 2.  Angiopoietin-like proteins: emerging targets for treatment of obesity and related metabolic diseases.

Authors:  Tsuyoshi Kadomatsu; Mitsuhisa Tabata; Yuichi Oike
Journal:  FEBS J       Date:  2010-12-23       Impact factor: 5.542

3.  Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results.

Authors:  Frank L Schmidt; In-Sue Oh; Theodore L Hayes
Journal:  Br J Math Stat Psychol       Date:  2007-11-13       Impact factor: 3.380

Review 4.  MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.

Authors:  Mohammed Eslam; Arun J Sanyal; Jacob George
Journal:  Gastroenterology       Date:  2020-02-08       Impact factor: 22.682

Review 5.  Nonalcoholic Fatty Liver Disease.

Authors:  Patrick H Sweet; Teresa Khoo; Steven Nguyen
Journal:  Prim Care       Date:  2017-12       Impact factor: 2.907

6.  The association of angiopoietin-like peptide 4 levels with obesity and hepatosteatosis in adolescents.

Authors:  Okan Dikker; Nevin Çetin Dağ; Mustafa Şahin; Emine Türkkan; Hüseyin Dağ
Journal:  Cytokine       Date:  2019-08-13       Impact factor: 3.861

7.  Angiopoietin-like 4 promotes intracellular degradation of lipoprotein lipase in adipocytes.

Authors:  Wieneke Dijk; Anne P Beigneux; Mikael Larsson; André Bensadoun; Stephen G Young; Sander Kersten
Journal:  J Lipid Res       Date:  2016-03-31       Impact factor: 5.922

8.  Angiopoietin-like protein 8/betatrophin correlates with hepatocellular lipid content independent of insulin resistance in non-alcoholic fatty liver disease patients.

Authors:  Beverly S Hong; Juan Liu; Jing Zheng; Weijian Ke; Zhimin Huang; Xuesi Wan; Xiaoying He; Haipeng Xiao; Yanbing Li
Journal:  J Diabetes Investig       Date:  2018-01-15       Impact factor: 4.232

Review 9.  Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications.

Authors:  Claudio Tana; Stefano Ballestri; Fabrizio Ricci; Angelo Di Vincenzo; Andrea Ticinesi; Sabina Gallina; Maria Adele Giamberardino; Francesco Cipollone; Richard Sutton; Roberto Vettor; Artur Fedorowski; Tiziana Meschi
Journal:  Int J Environ Res Public Health       Date:  2019-08-26       Impact factor: 3.390

Review 10.  A dual role of lipasin (betatrophin) in lipid metabolism and glucose homeostasis: consensus and controversy.

Authors:  Ren Zhang; Abdul B Abou-Samra
Journal:  Cardiovasc Diabetol       Date:  2014-09-13       Impact factor: 9.951

View more
  2 in total

1.  Role of ANGPTL8 in NAFLD Improvement after Bariatric Surgery in Experimental and Human Obesity.

Authors:  Carolina M Perdomo; Javier Gómez-Ambrosi; Sara Becerril; Víctor Valentí; Rafael Moncada; Eva M Fernández-Sáez; Leire Méndez-Giménez; Silvia Ezquerro; Victoria Catalán; Camilo Silva; Javier Escalada; Gema Frühbeck; Amaia Rodríguez
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

2.  Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.

Authors:  Brian A Bergmark; Nicholas A Marston; Marc S Sabatine; Stephen D Wiviott; Candace R Bramson; Madelyn Curto; Vesper Ramos; Alexandra Jevne; Julia F Kuder; Jeong-Gun Park; Sabina A Murphy; Subodh Verma; Wojtek Wojakowski; Steven G Terra
Journal:  Circulation       Date:  2022-04-03       Impact factor: 39.918

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.